MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bcp.15137

Медицинская библиотека · British journal of clinical pharmacology · 2021

A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor.

Brown Jack A, Bal Joanne, Simeoni Monica, Williams Peter, Mander Palwinder K, Soden Peter E, Daga Shruti, Fahy William A, Wong Gabriel K, Bloomer Jackie C, Erwig Lars, Cui Yi, Fernando Disala, Carnaghan Helen, Banham-Hall Edward J, Hopkins Sarah, Davis Bill G, Oliveira Joao J D, Prinjha Rabinder K

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

AIMS: GSK3358699 is a mononuclear myeloid-targeted bromodomain and extra-terminal domain (BET) family inhibitor which demonstrates immunomodulatory effects in vitro. This phase 1, randomized, first-in-human study evaluated the safety, pharmacokinetics, and pharmacodynamics of GSK3358699 in healthy male participants (NCT03426995).

METHODS

Part A (N = 23) included three dose-escalating periods of 1-40 mg of GSK3358699 or placebo in two cohorts in a single ascending-dose crossover design. Part C (N = 25) was planned as an initial dose of 10 mg of GSK3358699 or placebo daily for 14 days followed by selected doses in four sequential cohorts.

RESULTS

In part A, exposure to GSK3358699 and its metabolite GSK3206944 generally increased with increasing doses. The median initial half-life ranged from 0.7 to 1.1 (GSK3358699) and 2.1 to 2.9 (GSK3206944) hours after a single dose of 1-40 mg. GSK3206944 concentrations in monocytes were quantifiable at 1-hour post-dose following 10 mg of GSK3358699 and 1 and 4 hours post-dose following 20-40 mg. Mean predicted percentage inhibition of ex vivo lipopolysaccharide-induced monocyte chemoattractant protein (MCP)-1 reached 75% with 40 mg of GSK3358699. GSK3358699 did not inhibit interleukin (IL)-6 and tumour necrosis factor (TNF). The most common adverse event (AE) was headache. Four AEs of nonsustained ventricular tachycardia were observed across parts A and C. One serious AE of atrial fibrillation (part C) required hospitalization.

CONCLUSIONS

Single doses of GSK3358699 are generally well tolerated with significant metabolite concentrations detected in target cells. A complete assessment of pharmacodynamics was limited by assay variability. A causal relationship could not be excluded for cardiac-related AEs, resulting in an inability to identify a suitable repeat-dose regimen and study termination.

Для цитирования: Brown Jack A, Bal Joanne, Simeoni Monica, Williams Peter, Mander Palwinder K, Soden Peter E, Daga Shruti, Fahy William A, Wong Gabriel K, Bloomer Jackie C, Erwig Lars, Cui Yi, Fernando Disala, Carnaghan Helen, Banham-Hall Edward J, Hopkins Sarah, Davis Bill G, Oliveira Joao J D, Prinjha Rabinder K. A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor.. British journal of clinical pharmacology. 2021. DOI: 10.1111/bcp.15137.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.